Objective: We report the spectrum of immune-related adverse effects (irAEs) and outcome observed in a single-center cohort of 100 patients treated with immune checkpoint inhibitors in a routine clinical setting. Methods: Tumor entities included non-small cell lung cancer (n = 28), head and neck squamous cell carcinoma (n = 28), urothelial carcinoma (n = 7), and others (n = 37). Results: irAEs were documented in 49% of cases analyzed, and the most frequent manifestation consisted of immune-mediated skin rash (28%), colitis (9%), pneumonitis (8%), hypothyroidism (7%), or hepatitis (6%). Skin rash correlated with improved progression-free survival. Conclusion: Development of immune-related skin rash was found to correlate with favorable outcome, suggesting its practical feasibility as a potential predictive surrogate marker.
Oncol Res Treat

中文翻译：

---

皮疹的发展可预测基于抗 PD-1 和抗 CTLA4 的免疫检查点抑制剂治疗非小细胞肺癌或头颈部鳞状细胞癌的结果：单中心分析

目标：我们报告了在常规临床环境中接受免疫检查点抑制剂治疗的 100 名患者的单中心队列中观察到的免疫相关不良反应 (irAE) 和结果的范围。方法：肿瘤实体包括非小细胞肺癌（ n =28）、头颈部鳞状细胞癌（ n =28）、尿路上皮癌（ n =7）和其他（ n =37）。结果： 49% 的分析病例记录了 irAE，最常见的表现包括免疫介导的皮疹 (28%)、结肠炎 (9%)、肺炎 (8%)、甲状腺功能减退 (7%) 或肝炎。 6%）。皮疹与改善的无进展生存期相关。结论：发现免疫相关皮疹的发展与有利的结果相关，表明其作为潜在预测替代标志物的实际可行性。
肿瘤资源治疗